<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192749</url>
  </required_header>
  <id_info>
    <org_study_id>TBS-UCMSC-ASD001</org_study_id>
    <nct_id>NCT02192749</nct_id>
  </id_info>
  <brief_title>Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism</brief_title>
  <official_title>Open, Prospective Trial of Treatment of Autism Spectrum Disorders (ASD) Using Intravenous Infusion of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells
      administered intravenously (IV) in a series of 4 infusions every 3 months over the course of
      one year is safe and will induce a therapeutic effect in autism patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>89 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)</measure>
    <time_frame>13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)</measure>
    <time_frame>13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline macrophage-derived chemokine (MDC)</measure>
    <time_frame>13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline thymus and activation-regulated chemokine (TARC)</measure>
    <time_frame>13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Umbilical cord mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical cord mesenchymal stem cells</intervention_name>
    <arm_group_label>Umbilical cord mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  Ages 6 to 16

          -  Diagnostic and Statistical Manual of Mental Disorders (DSM IV) diagnosis of autism
             confirmed by Autism Diagnostic Observation Schedule (ADOS) and/or Autism Diagnostic
             Interview-Revised (ADI-R)

          -  No anticipated changes in treatment for the study duration (e.g., diet, nutrients)

          -  No additional biomedical treatments started 6 weeks prior to enrollment

          -  No changes in dietary management for 3 months prior to enrollment

          -  Ambulatory or require minimum support walking, per parent

          -  Able to sit still for 5 minutes or longer with a preferred toy item, per parent

          -  Adequate vision and hearing for the purposes of test administration, per parent

          -  Adequate arm-hand-finger coordination (i.e., able to point) for learning and
             cognitive tasks used in outcome measurement, per parent

          -  Stable and controlled mental disorder

          -  Under the care of a caregiver willing to participate by attending regularly scheduled
             appointments and completing the necessary measures

          -  Normal heavy metals test for lead and mercury levels performed within 30 days of
             first stem cell infusion

          -  Must provide name and specialty of specialist who has made Autism Spectrum Disorder
             (ASD) diagnosis

          -  Adequate financial means to cover $7,200 (US Dollars) plus travel expenses

        Exclusion Criteria:

          -  Significant prematurity at birth (less than 32 weeks gestation); or birth weight
             significantly below normal for gestational age (SGA - small for gestational age)

          -  mental retardation

          -  seizure disorder

          -  auto-immune conditions

          -  history of head trauma and other neurological or medical conditions

          -  Abnormal heavy metals test for lead and mercury performed within 30 days of first
             stem cell infusion

          -  Prior stem cell therapy of any kind
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson Novarro, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jorge Paz-Rodriguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Biosciences / Stem Cell Institute Panama</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stem Cell Institute</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 17, 2016</lastchanged_date>
  <firstreceived_date>July 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autism</keyword>
  <keyword>umbilical cord</keyword>
  <keyword>mesenchymal</keyword>
  <keyword>stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
